Paragon (ANZGOG-0903)
Anthony Bonaventura(Calvary Mater Newcastle Hospital), Michael Friedländer(Prince of Wales Hospital), Anna DeFazio(The University of Sydney), Rachel O’Connell(Royal Marsden NHS Foundation Trust), Alison Hadley(The University of Melbourne), Philip Beale(The University of Sydney), Cristina Mapagu(The University of Sydney), Linda Mileshkin(Peter MacCallum Cancer Centre), Peter Grant(The University of Melbourne), Orla McNally(Royal Women's Hospital), James Scurry, Katrin Marie Sjoquist(Australian Research Council), Julie Martyn(National Health and Medical Research Council), J.C.H. Goh(Queensland University of Technology)
Cited by 22
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k